Research programme: non-antibacterial macrolides - Melinta Therapeutics
Latest Information Update: 08 Nov 2017
At a glance
- Originator Optimer Pharmaceuticals
- Developer Cempra Pharmaceuticals; Melinta Therapeutics
- Class Macrolides
- Mechanism of Action Histone deacetylase modulators; LHRH receptor antagonists; Motilin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase Unknown Chronic obstructive pulmonary disease
- No development reported Cancer; Diabetic gastroparesis; Psoriasis
Most Recent Events
- 06 Nov 2017 Cempra Pharmaceuticals merged with Melinta Therapeutics to form Melinta Therapeutics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic gastroparesis in USA (PO)